Endocrine

, Volume 46, Issue 2, pp 256–262

Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI

  • Maria Ida Maiorino
  • Giuseppe Bellastella
  • Michela Petrizzo
  • Maria Rosaria Improta
  • Clementina Brancario
  • Filomena Castaldo
  • Laura Olita
  • Dario Giugliano
  • Katherine Esposito
Original Article

Abstract

To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patients on MDI; 38 out of the 43 patients considered eligible for CSII completed the study and the 82 remaining on MDI served as control group. Glycemic control and treatment satisfaction [diabetes treatment satisfaction questionnaire (DTSQ)] were evaluated in all patients at baseline and after 12 weeks. At baseline, the two groups were well matched for demographic characteristics and glycemic control. DTSQ score was lower in CSII group (21.1 ± 8.8 vs. 25.1 ± 7.1, P = 0.011). After 12 weeks, a similar decrease in HbA1C was observed in both groups [difference −0.3 % (95 % CI −0.6 to 0.1, P = 0.847)]. Mean amplitude glucose excursions, blood glucose standard deviation, and overall hypoglycemia were significantly reduced in CSII group. DTSQ overall score increased in CSII and decreased in MDI (difference between groups = 9.9, 95 % CI 8.0–12.0, P < 0.001), while perceived hyperglycemia and hypoglycemia decreased in CSII compared with MDI (difference: −2.5 and −2.0, respectively, P < 0.001 for both). Among young Type 1 diabetic patients in transition from Pediatrics, CSII showed a similar efficacy in reducing HbA1c compared with MDI, with less hypoglycemia and glycemic excursions, and was better in improving overall treatment satisfaction and the rate of perceived hyperglycemia and hypoglycemia.

Keywords

CSII Type 1 diabetes Transition Treatment satisfaction 

References

  1. 1.
    D.B. Petitti, G.J. Klingensmith, R.A. Bell, J.S. Andrews, D. Dabelea, G. Imperatore, S. Marcovina, C. Pihoker, D. Standiford, B. Waitzfelder, E. Mayer-Davis, SEARCH for Diabetes in Youth Study Group: Glycemic control in youth with diabetes: the SEARCH for diabetes in Youth Study. J. Pediatr. 155, 668–672 (2009)PubMedCrossRefGoogle Scholar
  2. 2.
    The DCCT Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329, 977–986 (1993)CrossRefGoogle Scholar
  3. 3.
    K.S. Bryden, D.B. Dunger, R.A. Mayou, R.C. Peveler, H.A. Neil, Poor prognosis of young adults with Type 1 diabetes: a longitudinal study. Diabetes Care 26, 1052–1057 (2003)PubMedCrossRefGoogle Scholar
  4. 4.
    V.S. Helgeson, K.A. Reynolds, P.R. Snyder, D.K. Palladino, D.J. Becker, L. Siminerio, O. Escobar, Characterizing the transition from paediatric to adult care among emerging adults with Type 1 diabetes. Diabet. Med. 30, 610–615 (2013)PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    D.S. Lotstein, M. Seid, G. Klingensmith, D. Case, J.M. Lawrence, C. Pihoker, D. Dabelea, E.J. Mayer-Davis, L.K. Gilliam, S. Corathers, G. Imperatore, L. Dolan, A. Anderson, R.A. Bell, B. Waitzfelder, SEARCH for Diabetes in Youth Study Group: Transition from pediatric to adult care for youth diagnosed with Type 1 diabetes in adolescence. Pediatrics 131, e1062–e1070 (2013)PubMedCrossRefGoogle Scholar
  6. 6.
    J.H. DeVries, F.J. Snoek, P.J. Kostense, N. Masurel, R.J. Heine, A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in Type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25, 2074–2080 (2002)PubMedCrossRefGoogle Scholar
  7. 7.
    J.L. Colquitt, C. Green, M.K. Sidhu, D. Hartwell, N. Waugh, Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health. Technol. Assess. 8, 1–171 (2004)Google Scholar
  8. 8.
    R.P. Hoogma, P.J. Hammond, R. Gomis, D. Kerr, D. Bruttomesso, K.P. Bouter, K.J. Wiefels, H. de la Calle, D.H. Schweitzer, M. Pfohl, E. Torlone, L.G. Krinelke, G.B. Bolli, 5-Nations Study Group: Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5-nations trial. Diabet. Med. 23, 141–147 (2005)CrossRefGoogle Scholar
  9. 9.
    EQuality1 Study Group–Evaluation of QUALITY of Life and Costs in Diabetes Type 1, A. Nicolucci, A. Maione, M. Franciosi, R. Amoretti, E. Busetto, F. Capani, D. Bruttomesso, P. Di Bartolo, A. Girelli, F. Leonetti, L. Morviducci, P. Ponzi, E. Vitacolonna, Quality of life and treatment satisfaction in adults with Type 1 diabetes: a comparison between continuous subcutaneous insulin infusion and multiple daily injections. Diabet. Med. 25, 213–220 (2008)PubMedCrossRefGoogle Scholar
  10. 10.
    J.C. Pickup, P. Hammond, NICE guidance on continuous subcutaneous insulin infusion 2008: review of the technology appraisal guidance. Diabet. Med. 26, 1–4 (2009)PubMedCrossRefGoogle Scholar
  11. 11.
    E.R. Seaquist, J. Anderson, B. Childs, P. Cryer, S. Dagogo-Jack, L. Fish, S.R. Heller, H. Rodriguez, J. Rosenzweig, R. Vigersky, Hypoglycemia and diabetes: a report of a workgroup of the american diabetes association and the endocrine society. Diabetes Care 36, 1384–1395 (2013)PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    F.J. Service, G.D. Molnar, J.W. Rosevear, E. Ackerman, L.C. Gatewood, W.F. Taylor, Mean amplitude of glycemic excursions: a measure of diabetic instability. Diabetes 19, 644–655 (1970)PubMedGoogle Scholar
  13. 13.
    A. Nicolucci, R. Giorgino, D. Cucinotta, G. Zoppini, M. Muggeo, S. Squatrito, A. Corsi, S. Lostia, L. Pappalardo, E. Benaduce, A. Girelli, F. Galeone, A. Maldonato, G. Perriello, P. Pata, G. Marra, G.A. Coronel, Validation of the Italian version of the WHOWELL-Being questionnaire (WHO_WBQ) and the WHO-Diabetes treatment satisfaction questionnaire (WHO_DTSQ). Diabetes Nutr. Metab. 17, 235–243 (2004)PubMedGoogle Scholar
  14. 14.
    E.L. Feldman, M.J. Stevens, P.K. Thomas, M.B. Brown, N. Canal, D.A. Greene, A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17, 1281–1289 (1994)PubMedCrossRefGoogle Scholar
  15. 15.
    R.P. Hoogma, A.J. Spijker, M. van Doorn-Scheele, T.T. van Doorn, R.P. Michels, R.G. van Doorn, M. Levi, J.B. Hoekstra, Quality of life and metabolic control in patients with diabetes mellitus Type 1 treated by continuous subcutaneous insulin infusion or multiple daily insulin injections. Neth. J. Med. Nov. 62, 383–387 (2004)Google Scholar
  16. 16.
    A. Peters, L. Laffel, The American Diabetes Association Transitions Working Group.: Diabetes care for emerging adults: recommendations for transition from pediatric to adult diabetes care systems. Diabetes Care 34, 2477–2485 (2011)PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    H.C. Yeh, T.T. Brown, N. Maruthur, P. Ranasinghe, Z. Berger, Y.D. Suh, L.M. Wilson, E.B. Haberl, J. Brick, E.B. Bass, S.H. Golden, Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann. Intern. Med. 157, 336–347 (2012)PubMedCrossRefGoogle Scholar
  18. 18.
    American Diabetes Association, Standards of medical care in diabetes 2013. Diabetes Care 36, S11–S66 (2013)PubMedCentralCrossRefGoogle Scholar
  19. 19.
    L. Hanberger, U. Samuelsson, B. Lindblad, J. Ludvigsson, A1C in children and adolescents with diabetes in relation to certain clinical parameters: the Swedish Childhood Diabetes Registry SWEDIABKIDS. Diabetes Care 31, 927–929 (2008)PubMedCrossRefGoogle Scholar
  20. 20.
    C.E. de Beaufort, P.G. Swift, C.T. Skinner, H.J. Aanstoot, J. Aman, F. Cameron, P. Martul, F. Chiarelli, D. Daneman, T. Danne, H. Dorchy, H. Hoey, E.A. Kaprio, F. Kaufman, M. Kocova, H.B. Mortensen, P.R. Njølstad, M. Phillip, K.J. Robertson, E.J. Schoenle, T. Urakami, M. Vanelli, Hvidoere Study Group on Childhood Diabetes 2005. Continuing stability of center differences in pediatric diabetes care: do advances in diabetes treatment improve outcome? The Hvidoere Study Group on Childhood Diabetes. Diabetes Care 30, 2245–2250 (2007)PubMedCrossRefGoogle Scholar
  21. 21.
    E.A. Doyle, S.A. Weinzimer, A.T. Steffen, J.A. Ahern, M. Vincent, W.V. Tamborlane, A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27, 1554–1558 (2004)PubMedCrossRefGoogle Scholar
  22. 22.
    G.B. Bolli, D. Kerr, R. Thomas, E. Torlone, A. Sola-Gazagnes, E. Vitacolonna, J.L. Selam, P.D. Home, Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in Type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 32, 1170–1176 (2009)PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    K. Esposito, P. Chiodini, A. Capuano, M. Petrizzo, M.R. Improta, D. Giugliano, Basal supplementation of insulin lispro protamine suspension versus insulin glargine and detemir for Type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Care 35, 2698–2705 (2012)PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    K. Esposito, A. Capuano, D. Giugliano, Humalog (lispro) for Type 2 diabetes. Expert Opin Biol Ther 12, 1541–1550 (2012)PubMedCrossRefGoogle Scholar
  25. 25.
    D. Bruttomesso, D. Crazzolara, A. Maran, S. Costa, M. Dal Pos, A. Girelli, G. Lepore, M. Aragona, E. Iori, U. Valentini, S. Del Prato, A. Tiengo, A. Buhr, R. Trevisan, A. Baritussio, In Type 1 diabetic patients with good glycemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine. Diabet. Med. 25, 326–332 (2008)PubMedCrossRefGoogle Scholar
  26. 26.
    I.B. Hirsch, B.W. Bode, S. Garg, W.S. Lane, A. Sussman, P. Hu, O.M. Santiago, J.W. Kolaczynski, Insulin Aspart CSII/MDI Comparison Study Group: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in Type 1 diabetic patients previously treated with CSII. Diabetes Care 28, 533–538 (2005)PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Maria Ida Maiorino
    • 1
    • 3
  • Giuseppe Bellastella
    • 1
  • Michela Petrizzo
    • 1
  • Maria Rosaria Improta
    • 1
  • Clementina Brancario
    • 1
  • Filomena Castaldo
    • 1
  • Laura Olita
    • 1
  • Dario Giugliano
    • 1
  • Katherine Esposito
    • 2
  1. 1.Department of Medical, Surgical, Neurological, Metabolic Sciences and GeriatricsSecond University of NaplesNaplesItaly
  2. 2.Department of Clinical and Experimental MedicineSecond University of NaplesNaplesItaly
  3. 3.Unit of DiabetologyUniversity Hospital at Second University of NaplesNaplesItaly

Personalised recommendations